Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide
08/01/2025 12:33
Jan 8 (Reuters) - Arch Biopartners Inc ARCH.V :
* ARCH BIOPARTNERS ANNOUNCES ONTARIO RESEARCH ETHICS BOARD
APPROVAL TO PROCEED WITH PHASE II TRIAL FOR LSALT PEPTIDE
TARGETING CARDIAC SURGERY-ASSOCIATED ACUTE KIDNEY INJURY
(CS-AKI)
Source text: ID:nGNXbHB3ts
Further company coverage: ARCH.V
((Reuters.Brief@thomsonreuters.com))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide